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Abstract
Background: Animal models of Parkinson's disease have been widely used for investigating the
mechanisms of neurodegenerative process and for discovering alternative strategies for treating
the disease. Following 10 injections with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 25
mg/kg) and probenecid (250 mg/kg) over 5 weeks in mice, we have established and characterized
a chronic mouse model of Parkinson's disease (MPD), which displays severe long-term neurological
and pathological defects resembling that of the human Parkinson's disease in the advanced stage.
The behavioral manifestations in this chronic mouse model of Parkinson's syndrome remain
uninvestigated. The health benefit of exercise in aging and in neurodegenerative disorders including
the Parkinson's disease has been implicated; however, clinical and laboratory studies in this area are
limited. In this research with the chronic MPD, we first conducted a series of behavioral tests and
then investigated the impact of endurance exercise on the identified Parkinsonian behavioral
deficits.
Results: We report here that the severe chronic MPD mice showed significant deficits in their gait
pattern consistency and in learning the cued version of the Morris water maze. Their performances
on the challenging beam and walking grid were considerably attenuated suggesting the lack of
balance and motor coordination. Furthermore, their spontaneous and amphetamine-stimulated
locomotor activities in the open field were significantly suppressed. The behavioral deficits in the
chronic MPD lasted for at least 8 weeks after MPTP/probenecid treatment. When the chronic MPD
mice were exercise-trained on a motorized treadmill 1 week before, 5 weeks during, and 8–12
weeks after MPTP/probenecid treatment, the behavioral deficits in gait pattern, spontaneous
ambulatory movement, and balance performance were reversed; whereas neuronal loss and
impairment in cognitive skill, motor coordination, and amphetamine-stimulated locomotor activity
were not altered when compared to the sedentary chronic MPD animals.
Conclusion: This study indicates that in spite of the drastic loss of dopaminergic neurons and
depletion of dopamine in the severe chronic MPD, endurance exercise training effectively reverses
the Parkinson's like behavioral deficits related to regular movement, balance and gait performance.
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Background
Parkinson's disease (PD) is a neurodegenerative disorder
afflicting millions of people especially in the growing
aging population. Patients with PD are typically debili-
tated with symptoms of muscular rigidity, impaired
movement, loss of balance, and tremor at rest. There is no
medical cure for PD. Current therapies are mainly targeted
at masking or reducing disease symptoms; however, such
measures are only temporary. A desirable approach for
intervening or slowing down the course of neurodegener-
ation in PD would be the search for alternative strategies
that either protect against neuronal loss (neuroprotec-
tion) or rejuvenate the defective cells (neurorestoration).
Exercise and balance training in the early disease stage
have been reported in a number of clinical studies show-
ing overall improvement in muscle strength, balance,
daily activities, motor performance, and ambulation in
PD patients [1-3]. However, the effect of exercise on neu-
rological and behavioral manifestations has not been con-
sistently presented in human PD or in laboratory models
of PD. Therefore, more research is necessary for validating
the long-term benefits of endurance exercise in PD.
Since its discovery in the early 1980's, 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) has been extensively
used by researchers to produce animal models of PD [4].
While humans and non-human primates are most suscep-
tible to MPTP in developing PD-like symptoms [5,6],
mouse models are widely used for studying the neurolog-
ical and pathological mechanisms underlying the degen-
eration of nigrostriatal dopaminergic neurons. Our
laboratory has developed and characterized a chronic
mouse model of Parkinson's disease (MPD) in which
mice are treated with MPTP and probenecid over a 5 week
period [7,8]. Probenecid inhibits the urinary and neuro-
nal clearance of MPTP and its metabolites, which causes a
potentiated loss of neurons in the substantia nigra and
persistently impairs dopamine (DA) transmission for at
least 6 months [7,8]. In contrast to the most commonly
used acute and subacute MPTP mouse models of PD in
which neurological and behavioral deficits are short-lived
and spontaneously reversed soon after the treatment, the
chronic MPD has long-lasting neurological deficits show-
ing many features resembling that of the Parkinson's syn-
drome, which include significant loss of cells, DA content
and terminal DA uptake in the nigrostriatal neurons,
detection of early neuronal apoptosis and delayed α-synu-
clein-positive inclusion bodies in the substantia nigra pars
compacta [9,10].
An important dimension of different MPTP mouse mod-
els is the manifestation of behavioral deficits that resem-
ble Parkinsonian signs and symptoms making them
useful for testing potential therapeutic agents. Given the
multitude of models varying in the amount of MPTP
administered and dosing schedules, published reports
have delineated an inconsistent picture of animal behav-
iors relevant to Parkinsonism, especially when mice are
observed in the open field. While a majority of studies
have shown reduced locomotor and rearing activities in
the MPTP-treated mice, other studies have reported either
no change in behavior or a development of hyperactivity
[11]. The discrepancies existed in behavioral results could
also be contributed by the differences in the duration of
observation or the time points after MPTP treatment at
which the assessment is made. Diminished cognitive abil-
ities such as slowed responses and dementia in human PD
have not been replicated in MPTP rodent models. There is
a paucity of studies exploring potential cognitive deficits
in MPTP-treated mice using tasks that relate to nigrostri-
atal function. However, following MPTP or 1-methyl-4-
phenyl-pyridinium treatment, behavioral tasks such as
passive and active avoidance, T-maze have been utilized
to detect memory/recognition skills that are associated
with the function of hippocampus, frontal cortex or olfac-
tory bulb [12-14].
In the present study, we first examined the motor and cog-
nitive skills in the chronic MPTP/probenecid-treated MPD
by monitoring their gait pattern, their performance on the
challenging beam and grid apparatus, in the cued and spa-
tial versions of Morris water maze (MWM), as well as in
the open field. We then exercise-trained the chronic MPD
and compared the outcome of endurance exercise on their
behavioral performances with that of the sedentary
chronic MPD.
Results
Exercise effect on neurological deficits in the severe 
chronic MPD
When mice were treated with 10 injections of a near max-
imal regimen of MPTP hydrochloride (25 mg/kg) and
probenecid (250 mg/kg) over 5 weeks, there was a persist-
ent loss of substantia nigra tyrosine hydroxylase immuno-
positive cells and depletion of striatal DA at least for a
survival span of 3–24 weeks [7,8]. Relevant to the present
study, which focused on animal behavioral monitoring
and analyses, for instance at 12 weeks after chronic MPTP/
probenecid treatment, the striatal DA level in the chronic
MPD was 1.92 ± 0.12 ng/mg tissue (N = 6), which was sig-
nificantly depleted when compared with the level found
in the chronic probenecid-treated controls, 14.85 ± 0.62
ng/mg tissue (N = 5), P < 0.0001. Continuous exercise
training for 12 weeks after MPTP/probenecid treatment
did not significantly raise the level of striatal DA (2.67 ±
0.29 ng/mg tissue, N = 6). Likewise, immunohistochemi-
cal and stereological analyses revealed a 72% loss of the
tyrosine hydroxylase positive neurons in the substantia
nigra pars compacta of the severe chronic MPD and exer-
cise training did not significantly reverse the cell loss.BMC Neuroscience 2009, 10:6 http://www.biomedcentral.com/1471-2202/10/6
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Exercise effect on gait pattern consistency
The animal step length and gait pattern consistency in the
control (N = 8), sedentary (N = 9), and exercise-trained
MPD (N = 5) were measured and compared. As shown in
Fig. 1, the statistical omnibus F indicated that there was a
significant difference in the averaged step length between
the three groups of animals [F (2, 19) = 255.78, P  =
0.0001]. The post-hoc analyses revealed that the sedentary
chronic MPD had a significantly shorter step length than
the chronic probenecid-treated control group (P  =
0.0001). Continuous exercise training for 12 weeks after
MPTP/probenecid treatment in the chronic MPD group
effectively reversed the step length deficit; thus, the aver-
aged step length exhibited in the exercise-trained chronic
MPD was significantly longer than that of the sedentary
chronic MPD group (P = 0.0001) and was not different
from that of the control group of animals.
The chronic MPD animals demonstrated a noticeable loss
of gait pattern consistency (Fig. 2). The statistical omnibus
F showed that there was a significant difference in the gait
pattern consistency over the entire period of recording
among the three groups of animals [F (2, 19) = 13.39, P =
0.0001]. The post-hoc analyses indicated that the seden-
tary chronic MPD mice had a more inconsistent gait pat-
tern (represented by a higher value of ApEn) than that of
the probenecid-treated control animals (P  = 0.0001).
When the chronic MPD group was exercise-trained for 12
weeks after MPTP/probenecid treatment, their consistency
of stepping pattern returned to normal; thus, the gait pat-
tern as expressed in mean ApEn for the exercised chronic
MPD was significantly lower than that of the sedentary
chronic MPD (P = 0.007) and was not statistically differ-
ent from that of the control group of animals. These data
suggest that the chronic MPD mice characteristically dis-
play a shorter step length and an inconsistent gait pattern
associated with severe dopaminergic neurodegeneration.
Long-term exercise training restored the gait performance
in the chronic MPD.
Exercise effect on the cued version of Morris water maze
One day after the last injection of MPTP/probenecid, the
chronic MPD (N = 10) demonstrated a significant impair-
ment in acquiring the cued version of the water maze task
showing significantly longer latencies when compared
with that of the control group of animals (N = 4), [F (1,
12) = 8.96, P = 0.01] (Fig. 3A). Similar results were found
when the test was given to the chronic MPD group 10
weeks after the chronic MPTP/probenecid treatment (N =
9); thus, they showed a significant deficit in learning the
task when compared to the control group (N = 9), [F (1,
16) = 8.26, P = 0.012] (Fig. 3B). Continuous exercise for
10 weeks after MPTP/probenecid treatment in the chronic
MPD (N = 5) did not significantly improve the animal's
performance in the cued version of the MWM when com-
pared with the sedentary chronic MPD mice (N = 9) [F (1,
12) = 0.37, P = 0.557] (Fig. 3B). These findings suggest
that the chronic MPD exhibits an immediate as well as a
long-term deficit in habitual learning that is linked to the
severe nigrostriatal neurodegeneration. Long-term exer-
cise training does not reverse the habitual learning deficit
in the chronic MPD.
Exercise effect on the spatial reference version of Morris 
water maze
In contrast to the cued version of water maze task, no sig-
nificant difference in the spatial reference version of water
maze learning was detected between the control and the
chronic MPD either short-term (1 week, N = 9, P > 0.05)
(Fig. 4A) or long-term after the MPTP/probenecid treat-
ment (8 weeks, N = 8, P > 0.05) (Fig. 4B). Exercise training
for 8 weeks after MPTP/probenecid treatment in the
chronic MPD did not significantly modify this behavior
(N = 8 for sedentary chronic MPD; N = 5 for exercised
chronic MPD) (Fig. 4B). These results indicate that
chronic MPTP/probenecid treatment does not affect the
hippocampus in a manner that would impair the animal's
ability to acquire the spatial reference learning task. Thus,
the baseline hippocampal function which has been
shown to be critical for accomplishing this task [15]
Effect of exercise on the step length in the chronic MPD Figure 1
Effect of exercise on the step length in the chronic 
MPD. The mean step length in the sedentary chronic MPD 
mice 12 weeks after MPTP/probenecid treatment was signifi-
cantly shorter than the probenecid-treated controls (*P = 
0.0001). Continuous exercise for 12 weeks after MPTP/
probenecid treatment in the chronic MPD completely 
reversed the step length deficit as detected in the sedentary 
chronic MPD group (**P = 0.0001). The mean step length in 
the control group and exercised chronic MPD group were 
not statistically different.BMC Neuroscience 2009, 10:6 http://www.biomedcentral.com/1471-2202/10/6
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Effect of exercise on the gait pattern in the chronic MPD Figure 2
Effect of exercise on the gait pattern in the chronic MPD. The representative pattern of step length time series from a 
probenecid control mouse, a sedentary chronic MPD mouse, and an exercised chronic MPD mouse 12 weeks after MPTP/
probenecid treatment were shown at top. The calculated gait pattern certainties in terms of approximate entropy (ApEn) for 
the three groups of animals were respectively shown in the bar graph below. A larger ApEn value denotes a more variable 
movement pattern, which was significantly demonstrated by the sedentary chronic MPD when compared with the control 
group of animals (*P = 0.0001). The ApEn value for the exercised chronic MPD was significantly lower suggesting a more con-
sistent gait pattern than that of the sedentary chronic MPD (**P = 0.007). The gait pattern consistency (ApEn value) in the con-
trol group and exercised chronic MPD group were not statistically different.
 Probenecid control                          Sedentary MPD                               Exercised MPD BMC Neuroscience 2009, 10:6 http://www.biomedcentral.com/1471-2202/10/6
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Exercise effect on learning of the cued version of the Morris water maze (MWM) in the chronic MPD Figure 3
Exercise effect on learning of the cued version of the Morris water maze (MWM) in the chronic MPD. (A) One 
day and (B) 10 weeks after MPTP/probenecid treatment, the chronic MPD group of mice showed significant impairment in 
learning the cued version of the MWM when compared with the controls (A, *P = 0.01 and B, *P = 0.012, respectively). (B) 
Continuous exercise for 10 weeks after MPTP/probenecid treatment did not alter the learning deficit for the cued version of 
the MWM in the chronic MPD (**P = 0.557, when compared to the sedentary chronic MPD).BMC Neuroscience 2009, 10:6 http://www.biomedcentral.com/1471-2202/10/6
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Exercise effect on learning of the spatial reference version of the MWM in the chronic MPD Figure 4
Exercise effect on learning of the spatial reference version of the MWM in the chronic MPD. (A) One week and 
(B) 8 weeks after MPTP/probenecid treatment, the chronic MPD group of mice showed no impairment in learning the spatial 
reference version of the MWM when compared to the controls. (B) Continuous exercise for 8 weeks after MPTP/probenecid 
treatment did not alter the learning for the spatial reference version of the MWM in the chronic MPD.BMC Neuroscience 2009, 10:6 http://www.biomedcentral.com/1471-2202/10/6
Page 7 of 14
(page number not for citation purposes)
appears to be intact in the chronic MPD and is not affected
by exercise training.
In order to exclude the possibility that chronic MPTP/
probenecid treatment might influence the overall ability
of swimming in mice, we further compared the swimming
speed in the two groups of animals. Briefly, a narrow (6
cm) path was created with two wooden planks along the
diameter (120 cm) of the water maze without an escape
platform. The time latency for each mouse to swim across
the entire path based on two trials (ITI = 30 sec) was aver-
aged and statistically analyzed. The mean time for the
control group (N = 9) and chronic MPD group (N = 10)
to swim across the path were 4.89 ± 0.21 s and 4.80 ± 0.16
s, respectively, which were not statistically different. This
observation confirms that MPTP/probenecid treatment in
the chronic MPD does not significantly impair the ani-
mal's physical ability for swimming that might interfere
with their ability to locate the escape platform in the water
maze.
Exercise effect on challenging beam and grid tasks
We used the challenging beam and grid tasks in this study
to examine the animal's balance and motor coordination
skills. Two weeks after MPTP/probenecid treatment, the
chronic MPD group (N = 10) displayed a significantly
higher number of foot slips on the challenging beam than
that of the control group (N = 10), [F (1, 18) = 4.86, P =
0.041] (Fig. 5). Same results were obtained from the
chronic MPD 10 weeks after treatment (N = 10), which
had significantly more foot slips on the challenging beam
than the probenecid-treated control group (N = 10) [F (1,
18) = 7.52, P = 0.013] (Fig. 5). Continuing exercise train-
ing for 10 weeks after MPTP/probenecid treatment (N =
7), these animals had significantly less foot slips on the
challenging beam when compared with the sedentary
chronic MPD (N = 10) [F (1, 15) = 8.18, P = 0.01] (Fig. 5)
Using a grid walk test, we also observed that the chronic
MPD (N = 10) had a significantly higher percentage of
foot slips through the grid openings than that of the con-
trol mice 2 weeks (N = 10) [F (1, 18) = 5.05, P = 0.037],
and 10 weeks (N = 10) [F (1, 18) = 8.27, P = 0.01] after
chronic MPTP/probenecid treatment (Fig. 6). However,
continuous exercise training for 10 weeks after MPTP/
probenecid treatment did not significantly improve their
grid walk performance (N = 10 for sedentary chronic
MPD; N = 7 for exercised chronic MPD) (Fig. 6).
The data from the challenging beam and grid tasks
together demonstrate that the chronic MPD mice have
impaired balance and motor coordination skills, which
persisted for at least 10 weeks after MPTP/probenecid
treatment. Exercise training improves the balancing skill
but fails to restore the motor coordination skill in the
chronic MPD.
Exercise effect on open field behaviors
We further recorded the locomotor behaviors in mice in
the open field 11 weeks after chronic probenecid or
MPTP/probenecid treatment. To obtain the basal levels of
activity, control and chronic MPD were injected with
saline and their ambulation was observed for 3 hours. The
total distance traveled (m) by the chronic MPD under
basal conditions (N = 10) was significantly lower than
that of the chronic probenecid-treated control animals (N
= 9), [F (1, 17) = 5.58, P = 0.03) (Fig. 7). When the chronic
MPD animals were exercise trained for 11 weeks after
MPTP/probenecid treatment (N = 7), they completely
recovered from the spontaneous movement deficit when
compared to the sedentary chronic MPD (N = 10), [F (1,
15) = 6.84, P = 0.02] (Fig. 7).
Three days after monitoring the spontaneous movement,
each animal received a single dose of amphetamine (3
mg/kg, i.p) and the drug-induced locomotor activities
were recorded for 3 hours. The amphetamine-challenged
ambulatory activity detected in the chronic MPD (N = 10)
Exercise effect on balance performance on a challenging  beam in the chronic MPD Figure 5
Exercise effect on balance performance on a chal-
lenging beam in the chronic MPD. Two and 10 weeks 
after MPTP/probenecid treatment, the chronic MPD group of 
mice had significantly more limb slips than the controls while 
traversing the challenging beam (*P = 0.041 and *P = 0.013, 
respectively). The chronic MPD, when continuously exer-
cised for 10 weeks after MPTP/probenecid treatment, had 
significantly less foot slips on the challenging beam than the 
sedentary chronic MPD (**P = 0.01).BMC Neuroscience 2009, 10:6 http://www.biomedcentral.com/1471-2202/10/6
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was also significantly lower than that of the probenecid-
treated control mice (N = 9), [F (1, 17) = 8.67, P = 0.009]
(Fig. 8). Continuous exercise training for 11 weeks after
MPTP/probenecid treatment (N = 7) did not significantly
change the amphetamine-stimulated movement when
compared to the sedentary chronic MPD (N = 10), [F (1,
15) = 1.92, P = 0.186] (Fig. 8). Our data that showed
diminished spontaneous and amphetamine-stimulated
behavioral responses in the chronic MPD would implicate
a long-term locomotor dysfunction corresponding to the
neurological dopaminergic deficit in the nigrostriatal
tract. Exercise training effectively reverses the spontaneous
movement deficit but does not significantly reverse the
depression of amphetamine-stimulated movement as
exhibited in the chronic MPD.
Discussion
Behavioral manifestations in the chronic MPD
The present study examined and compared the cognitive
and motor skills in the chronic MPD with severe nigrostri-
atal neurodegeneration shortly after and beyond 8 weeks
of Parkinson's syndrome development. In association
with marked loss of nigrostriatal dopaminergic cells and
DA content, we observed that the chronic MPD showed
significant deficits in (1) gait consistency pattern; (2) the
Exercise effect on motor coordination on a walking grid in  the chronic MPD Figure 6
Exercise effect on motor coordination on a walking 
grid in the chronic MPD. Two and 10 weeks after MPTP/
probenecid treatment, the chronic MPD group of mice had 
significantly higher percentage of limb slips over steps than 
the controls while walking on a perforated grid (*P = 0.037 
and *P = 0.01, respectively). Continuous exercise for 10 
weeks after MPTP/probenecid treatment did not significantly 
improve the grid walk performance in the chronic MPD (**P 
= 0.485).
Exercise effect on the spontaneous locomotor activity in the  chronic MPD Figure 7
Exercise effect on the spontaneous locomotor activ-
ity in the chronic MPD. The horizontal movement 
expressed as cumulative distance traveled by each animal was 
recorded over 180 min. The spontaneous locomotor activity 
in the chronic MPD mice 11 weeks after MPTP/probenecid 
treatment was significantly lower than that of the chronic 
probenecid-treated control mice (*P = 0.03). Continuous 
exercise for 11 weeks after MPTP/probenecid treatment in 
the chronic MPD completely reversed the spontaneous 
movement deficit as detected in the sedentary chronic MPD 
group (**P = 0.02).
Exercise effect on the amphetamine-induced locomotor  activity in the chronic MPD Figure 8
Exercise effect on the amphetamine-induced loco-
motor activity in the chronic MPD. The amphetamine (3 
mg/kg, i.p.)-induced locomotor activity in the chronic MPD 
mice 11 weeks after MPTP/probenecid treatment was signifi-
cantly lower than that of the chronic probenecid-treated 
control mice (*P = 0.009). Following 11 weeks of exercise 
training, no statistically significant recovery of the ampheta-
mine-stimulated movement was observed when comparing 
to the sedentary chronic MPD (**P = 0.186).BMC Neuroscience 2009, 10:6 http://www.biomedcentral.com/1471-2202/10/6
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learning capacity when challenged with the cued version
of water maze; (3) balance and motor coordination skills
on the challenging beam and walking grid; (4) the spon-
taneous and amphetamine-stimulated locomotor behav-
iors in the open field. Noticeably, these diminished
behavioral responses lasted for at least 8–12 weeks after
MPTP/probenecid treatment. The inhibited behavioral
manifestations were apparently associated with the severe
loss of nigrostriatal transmission, since the function of the
hippocampus remained unaffected as shown by their
unaltered ability to learn the spatial reference version of
the water maze.
One of the clinical features of advanced PD is truncal
rigidity that creates difficulty for affected patients to main-
tain an upright posture and a normal gait; thus, while
walking they tend to take small steps in a hasty pace,
which would result in frequent falls [16]. Totally replicat-
ing the PD-liked postural and gait deficits in quadrapedal
rodents is not expected to be physiologically feasible. At
best, a gait analysis technique that measures and com-
pares the variability of stride length and stepping pattern
may be applied to rodent models of PD [17]. Indeed, as
demonstrated in the present study, the gait analysis
revealed that the severe chronic MPD has a relatively
shorter stepping length and a less consistent gait pattern
certainty than the non-Parkinsonian mice. Therefore, this
technique does provide a reliable approach for assessing
the experimental outcomes and for predicting the severity
of neurological lesions comparable to the clinical gait var-
iability as reported in human PD [18,19].
Human studies through several neuropsychological tests
have reported that PD patients without dementia have a
reduced ability for acquiring cue-based probability learn-
ing tasks with no impairment in the process of recollective
memory; these findings suggest that neostriatum plays an
important role not only for learning and performing
motor skills but is also essential for processing the grad-
ual, incremental learning of associations known as habit-
ual learning [20,21]. In the rodent literature, the cued
version of the MWM is a stimulus-response or habitual
task, which requires an intact network of the basal ganglia
in order for successfully acquiring the task [45]. Therefore,
lesions present in the basal ganglia would suppress the
learning ability of rodents to associate a unique cue
located on the platform as a visual sign with a safe landing
place in the water maze. In the present study and to our
knowledge for the first time, we tested and confirmed that
a deficit in the cued version of the MWM could be demon-
strated not only shortly after MPTP/probenecid treatment
but could also be associated with long-term and severe
nigrostriatal neurodegeneration in the chronic MPD [9].
Considering that various attempts for behaviorally charac-
terizing different MPTP mouse models of PD have pro-
duced inconsistent results so far, the findings of this study
indicate that the cued version of the MWM would be a
useful test for assessing short-term and long-term habitual
learning deficit associated with MPTP-induced lesions in
the basal ganglia of mice.
As mentioned earlier, the spatial reference version of the
MWM requires the rodents to use various cues from the
environment in the close vicinity of the maze for locating
the escape platform and this skill is dependent on the
integral function of the hippocampus. Several dissocia-
tion studies have clearly distinguished the two cognitive
learning systems independently involving the hippocam-
pus and the basal ganglia [22,23]. When MPTP was
administered centrally or through nasal inhalation, rats
developed short-term impairment in their learning of the
cued version but not the spatial reference version of the
MWM task [24-26]. This notion is substantiated by the
observations of the current study, in which we detected no
change in the performance of the spatial reference version
of the MWM in mice 1 week or 8 weeks after MPTP/
probenecid treatment. Hence, there is no evidence sug-
gesting that chronic MPD mice have developed learning
deficits linked to the hippocampus, and we have not
found published reports describing a direct toxic effect of
MPTP on the hippocampus that would dysregulate the
cognitive function.
In this study, we strove to determine whether the order of
administering the two different versions of MWM to the
same animal would impact the outcome of learning the
respective task. We therefore randomly altered the
sequence for conducting the two versions of MWM in the
chronic MPD. The results were consistent regardless
which order of the task that we used first, because it is
apparent that they are functionally regulated by two dis-
tinctive neuronal network systems. Furthermore, we per-
formed a control experiment illustrating that the chronic
MPD mice did not have physical impairment that would
hinder their ability for swimming, since the amount of
time for them to swim across the maze without visual cues
was indifferent from that of the control mice.
The extrapyramidal system of the basal ganglia has long
been recognized for its control and refinement of motor
performance and coordination [27,28]. We examined the
short-term and long-term motor and balancing skills in
the chronic MPD animals by monitoring their walk on a
challenging beam and a wired grid. The challenging beam
task has been successfully used for demonstrating motor
deficit in a transgenic mouse model of PD that overex-
presses  α-synuclein [48]. The grid walk task has been
widely used for testing animal models for spinal injury,
ischemia and traumatic brain injury [29,49]. Both tests
confirmed that the chronic MPD mice exhibited motorBMC Neuroscience 2009, 10:6 http://www.biomedcentral.com/1471-2202/10/6
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and balance deficits not only within 2 weeks but also per-
sisted for at least 10 weeks after the MPTP/probenecid
treatment when compared to the control animals. The
prolonged motor dysfunction displayed by the chronic
MPD mice appears to resemble the movement disability
and imbalance in the human PD.
The gradual loss of nigrostriatal neurons and depletion of
the neurotransmitter, DA have been considered as the
basis of locomotor deficit in Parkinson's disorder, which
can be demonstrated in laboratory animals by monitoring
their ambulatory movement in the open-field. In the
present study, we measured both the spontaneous and the
amphetamine-stimulated movement in the chronic MPD
and we found that these animals exhibited a long-term
deficit in horizontal movement whether the striatal DA
system was unstimulated or stimulated. These observa-
tions support the concept that the level of DA in the stri-
atal terminal vesicles is considerably depleted as
demonstrated in the chronic MPD [7,8]; thus the normal
release and stimulated release of the stored vesicular DA
through the indirect action of amphetamine are both
diminished. Recently, similar abnormalities in ampheta-
mine-challenged horizontal movement in the open field
that correlate with increasing levels of striatal DA deple-
tion in an acute MPTP mouse model of PD have also been
reported implicating that the amphetamine-stimulated
assessment of movement in PD models can be validated
[30].
Following an acute single injection with a moderate dose
of amphetamine, it is known that the drug is taken up by
the terminal dopaminergic transporter before it triggers
the release of stored DA from vesicles. Nevertheless, the
amphetamine effect is not specific to the dopaminergic
neurons. It can be taken up by other monoamine terminal
transporters in the same fashion and the involvement of
norepinephrine and serotonin release may further modify
the ambulation of the animal [31]. It is also possible that
amphetamine exerts its effects on locomotion via the ter-
minal DA2 autoreceptors [32]. MPTP is shown to reduce
the DA2 receptor mRNA expression [33] and mice with
knockout DA2 receptors have exhibited reduced spontane-
ous locomotion [34,35]. Taken together, the reduced
spontaneous and amphetamine-stimulated ambulatory
movement detected in the chronic MPD could be contrib-
uted by either or both the depletion of DA content in the
storage vesicles and a down-regulation of the DA2 recep-
tors. The latter possibility involving the DA2 receptors
requires further investigation in the chronic MPD mice.
Effect of endurance exercise on behavioral deficits in the 
chronic MPD
Following the investigation of behavioral deficits in the
chronic MPD, we further studied the effect of endurance
exercise on their behavioral deficits. Although continuous
exercise for 12 weeks after MPTP/probenecid treatment
did not significantly reverse the neurological deficit in the
nigrostriatal dopaminergic system in this severe animal
model of Parkinsonism, we are gratified to detect that
endurance exercise training significantly invigorated the
spontaneous movement and restored the gait pattern con-
sistency and balance in the chronic MPD. However, exer-
cise training did not have the same positive impact on the
motor coordination and cognitive learning deficit that are
also associated with the severe nigrostriatal neuron degen-
eration.
Behavioral assessment of exercise effect has been reported
in several animal models of Parkinsonism. In the rat
model of Parkinsonism induced by 6-hydroxydopamine,
either voluntary running or treadmill paced exercise atten-
uated DA loss in the striatum with or without significant
recovery of behavioral deficits [36-38]. The neuronal
recovery in 6-hydroxydopamine-treated rats triggered by
exercise is associated with an increase of the striatal glial
cell line-derived neurotrophic factor [39]. In an acute
mouse model of Parkinsonism induced by MPTP, tread-
mill exercise ameliorates behavioral deficits and reverses
several striatal dopaminergic indices including the loss of
DA, TH-immunoreactivity, and DA transporter levels
when compared to the sedentary Parkinsonian animals
[36]. In another study, high-intensity treadmill exercise in
acute MPTP-treated mice leads to behavioral recovery;
however, the striatal expression of DA transporter is
down-regulated and the expression of TH is not changed
[33]. Differences in the exercise results obtained from ani-
mal models of Parkinsonism could be due to experimen-
tal variables such as the age and species of the animal, the
method and severity of the induced nigrostriatal lesion,
and the type and intensity of the exercise regimen.
The chronic MPD that is induced by MPTP/probenecid
and used in this study affords a neurodegenerative model
for PD. With 10 doses of MPTP (25 mg/kg) plus probene-
cid (250 mg/kg), the chronic MPD attains a severe level of
neurodegeneration showing neurochemical, histological,
behavioral and pathological characteristics resembling
that of PD at advanced stages [9]. Offering exercise train-
ing to the severe chronic MPD animals does not appear to
produce neuroprotective or neuroregenerative effect to
the dopaminergic neurons. It is not expected that exercise
or other pharmacotherapeutic approaches would deliver
such promises in the severe chronic MPD or advanced PD,
in which the majority of neurons and neurotransmitters
are already irreparably lost. However, it is so encouraging
to learn based on the observations of this study that exer-
cise training can effectively reverse certain behavioral def-
icits, like impaired movement, imbalance and
inconsistent gait pattern that are associated with the Par-BMC Neuroscience 2009, 10:6 http://www.biomedcentral.com/1471-2202/10/6
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kinsonian syndrome in spite of the existing severe loss of
dopaminergic neurons and neurotransmitter. It is not
clear why other behavioral abnormalities, like the
impaired cognitive learning and motor coordination
skills, are not recovered by exercise training. It is possible
that intact nigrostriatal system and adequate level of stri-
atal DA are obligatory for maintaining these behaviors,
like in the case of open field study with amphetamine that
its pharmacological action is dependent on the undam-
aged DA tract for eliciting movement hyperactivity. Addi-
tional studies are necessary for exploring and
substantiating such a hypothesis.
Conclusion
The results of this study demonstrate that the severe
chronic MPD mice exhibit a wide range of behavioral phe-
notypes that represent symptoms comparable to that of
the advanced PD. It is noteworthy that these behaviors
persist and allow for several months of study. Combined
with the neurochemical and pathological characteristics
that we have previously reported in this chronic MPD,
these behavioral tests would afford confirmation of
dopaminergic neurodegeneration without requiring addi-
tional animal sacrifice for neurochemical and neuroana-
tomical analyses. The long-term neurological and
behavioral deficits that are characterized in this chronic
MPD would make this model more useful for exploring
novel therapeutic targets for treating PD.
Endurance exercise has been widely advocated for main-
taining healthy life in general, and for slowing down aging
and neurodegenerative processes. The benefit of exercise
on cardiovascular adaptation has been well studied and
recognized; however, the information about exercise
effect on neurological improvement and associated
behaviors is still limited. This study demonstrates that in
the severe chronic MPD with behavioral deficits compara-
ble to the advanced Parkinsonian syndrome, exercise
training can bring anomalous movement, balance and
gait pattern back to the state of normalcy, even though the
neurological indicators remain severely impaired. There-
fore, exercise has a beneficial impact on reversing certain
behavioral deficits associated with Parkinsonian-like neu-
rodegeneration.
Methods
Chronic mouse model of Parkinson's disease
Four to six-month old, male, C57BL/6 mice (Harlan
Sprague Dawley, Inc., Indianapolis, IN, USA) were housed
in single cages with food pellets and water available ad
libitum. The room was maintained at a constant tempera-
ture and humidity on a 12-h/12-h light/dark cycle. All
experiments took place during light time. All animal treat-
ments were carried out strictly in accordance to the
National Institute of Health Guide for the Care and Use of
Laboratory Animals (NIH Publications No. 80-23, revised
1996) and were approved by the Institutional Animal
Care and Use Committees from the University of Hou-
ston. Our experimental procedures did not cause signifi-
cant animal suffering. A total of 58 mice were used in the
present study. For the behavioral testing, each animal
within a cohort was tested only once for all the different
tasks.
To prepare the chronic MPD with severe neurodegenera-
tion, mice were injected with a total of 10 doses of MPTP
hydrochloride (25 mg/kg/injection in saline, s.c.) in com-
bination with an adjuvant, probenecid (250 mg/kg/injec-
tion dissolved in dimethyl sulfoxide, i.p.) as previously
described [8]. The 10 doses were administered on a five-
week schedule with an interval of 3.5 days between injec-
tions. Control mice were treated with probenecid only.
MPTP hydrochloride and probenecid were purchased
from Sigma Chemical Co. (St. Louis, MO, USA). Safety
precautions for the use of MPTP during chemical prepara-
tion and animal injections were taken according to the
procedures previously described [40].
Endurance exercise training
A six-lane motorized rodent treadmill (Columbus
Instruments, Columbus, OH, USA) was utilized for exer-
cise training. Mice were exercise trained one week before,
5 weeks during the chronic MPTP/probenecid treatment,
and exercise was continued after the last treatment till
two day before experiment as shown in the following
scheme:
The exercised group of animals was trained on the tread-
mill running for 5 days/week, 40 min/day at a speed up to
15 m/min (5 min at 6 m/min, 5 min at 9 m/min, 20 min
at 12 m/min, 5 min at 15 m/min, and 5 min at 12 m/min)
with 0° of inclination. Using this treadmill exercise proto-
col in our laboratory, the chronic MPD mice were able to
go through the training with minimal requirement for
external stimuli or manual prodding, yet the animals
developed physical endurance after 4 weeks showing car-
diorespiratory and metabolic adaptations comparable to
those seen in human subjects undergoing continuous
exercise training [41]. Sedentary mice did not exercise;
however, they were transported daily to the training room
so that they were exposed to the same environment as the
exercised group of animals.BMC Neuroscience 2009, 10:6 http://www.biomedcentral.com/1471-2202/10/6
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Gait pattern measurement
The method for gait pattern determination and data
expression in mice has been previously described [42].
Briefly, twelve weeks after chronic MPTP/probenecid
treatment, mice were videotaped in the sagittal plane with
a 60 Hz camera as they ran on a motorized treadmill at a
speed of 10 m/min, 0° inclination. All gait data were col-
lected on the same day and treadmill. The positions of the
base of the tail, right fore and hind feet were manually dig-
itized from the videos with commercially available
motion capture software (ViconPeak, Centennial, CO). To
account for any variation in the mouse's position on the
treadmill, we calculated the displacement of the feet rela-
tive to the base of the tail. These newly defined feet posi-
tions were used to determine the selected step lengths for
85 consecutive steps. We calculated the mean step length
used by each of the respective experimental groups.
Approximate entropy (ApEn), which is a regularity statis-
tic that evaluates the likelihood that similar patterns in the
time series will be present at a later time period was used
for determining the consistency of the mouse's step
lengths [43]. Accordingly, a time series with a more con-
sistent pattern has an ApEn value closer to zero, while a
time series with a less consistent or irregular pattern has
an ApEn value closer to two. A higher ApEn has previously
been validated and associated with movement dysfunc-
tions found in the elderly and in individuals with PD [44].
Cued and spatial versions of Morris water maze
The apparatus used was a circular white tub with an inside
diameter of 120 cm. It was filled with water at room tem-
perature (24°C), which was made opaque in color by dis-
solving a white non-toxic dye (Chromatemp, Chroma,
Lititz, PA, USA). The water level reached at 15 cm below
the top edge of the tub. The escape target was a white hex-
agonal platform with equilateral sides (7.5 cm per side),
which was submerged 1 cm below the water surface. A day
before testing was conducted, mice were pre-trained by
exposing them to the water maze apparatus with the plat-
form located in the center of it. Specifically, mice were first
placed on the platform for 20 sec, followed by three con-
secutive trials consisting of releasing them in the water at
a location approximately 10 cm away from the platform
and allowing them to find the platform and stay on it for
another 20 sec. If the mouse failed to locate the platform
and/or to stay on it, then it was guided to complete the
task by the experimenter.
We tested the animals in two different versions of MWM.
The cued version of the MWM had an escape platform
with a rod (12.5 cm in length, 1 cm in diameter) glued
onto the platform and with a plastic ball (2.5 cm diame-
ter) on the top of the rod. Both the rod and the ball had
black and white stripes making them easily visible in the
water maze environment. The position of the platform
was altered for each trial. The cued version of MWM is a
habitual learning task associated with the functionality of
the striatal network [45]. This test was administered in our
study one day (short-term) and 10 weeks (long-term)
after the chronic MPD treatment.
The second version of the MWM that we used was the
spatial reference test, in which the animal subjects relied
on prominent spatial cues in the surrounding environ-
ment outside the maze, such as posters and laboratory
objects on a desk in fixed positions. The escape platform
had no visual cues and was kept in one position during
all trials. The spatial reference version of the MWM meas-
ures the ability of cognitive learning that is associated
with the integrity of the hippocampal network [46,47].
This test was administered in our study one week (short-
term) and 8 weeks (long-term) after the chronic MPD
treatment.
In both versions of MWM test, the mouse was released fac-
ing the wall of the water maze from a different starting
point in each trial and was given 60 sec to find the plat-
form. If the animal failed to find the platform, it would be
gently led to it by the experimenter. In either case the ani-
mal was left on the platform for 20 sec, dried, and
returned to its home cage. Each mouse was tested with 4
trials per day for 4 or 6–10 consecutive days (cued and
spatial reference version, respectively) with an inter-trial
interval (ITI) of 30 to 40 min. For statistical analysis, the
latency (in seconds) for each animal to reach the platform
based on four daily trials was averaged and considered as
a single score for the day.
Challenging beam and grid tasks
We further monitored the ability of the chronic MPD in
maintaining balance and motor coordination on a chal-
lenging beam and a wired grid apparatus 2 weeks (short-
term) and again 10 weeks (long-term) after chronic MPD
treatment. The challenging beam was a 1 m long wooden
beam suspended 23 cm above a bench top, which was
covered with soft pads to protect the mouse in case of a
fall. The beam was divided in four gradually narrowing
sections (25 cm/section) leading to the mouse's home
cage. The beam widths of the four sections were 3.5, 2.5,
1.5, and 0.5 cm in decreasing order [48]. The beam was
covered with surgical tape that provided sufficient surface
traction for the animals to walk on. There were 1 cm wide
ledges hanging 1 cm below each side of the beam to
encourage the mice to use their normal gait strategies even
when their limbs slipped. All mice were pre-trained for
two consecutive days (5 trials/day, ITI = 10–12 sec) on tra-
versing the beam. On the third day, each mouse was given
5 trials (ITI = 10–12 sec) and the average number of vide-
otaped limb slips per trial was used for statistical analysis.BMC Neuroscience 2009, 10:6 http://www.biomedcentral.com/1471-2202/10/6
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Slips were counted only while the mouse was in forward
motion.
For the grid task, mice were allowed to explore and walk
on a square metallic wired grid (30 cm × 30 cm) with
square openings (1.25 cm/side) across the surface, which
was mounted 50 cm above a bench top with soft pads
underneath to protect the mouse in case of a fall. Each
mouse was videotaped for 3 minutes while walking on the
grid [49]. Only full limb slips and not partial foot entries
through the grid openings were counted. The percentage
of slips over total number of steps taken was used for anal-
ysis.
Open field
We measured saline-injected baseline and amphetamine
(3 mg/kg, i.p., Sigma, St. Louis, MO, USA)-challenged
ambulatory activity in the open-field with an automated
behavioral monitor equipped with an X-Y arrangement of
infrared photoreceptor beams (16 per side) (Opto-Var-
imex, Columbus Instruments, Columbus, OH, USA).
Each mouse was placed in a clear, open-top, square Plex-
iglas box (40 × 40 × 20 cm) within the monitor in a sub-
dued room. As introduced earlier, since open field
behaviors in mice shortly after MPTP treatment tend to be
overly variable, in this study we monitored the open field
ambulation limited to long-term (11 weeks) after the
induction of chronic Parkinsonism. The total distance
(m) traveled by each mouse was cumulated after every 15
min and plotted for a period of 3 hr.
Statistical analysis
For gait pattern measures, two one-way ANOVA with
Tukey HSD post-hocs were used to find statistical differ-
ences in the ApEn values and mean step lengths. The data
collected for the water maze and open field behaviors
were analyzed by using a mixed ANOVA with different
time points as the within subjects factor and the treated
and untreated groups as the between subjects factor. For
the grid and challenging beam tasks, simple ANOVA was
used (SPSS 12). All results were considered statistically
significant when P < 0.05.
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